-
Mashup Score: 5Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer - 10 month(s) ago
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial - Nature Cancer - 10 month(s) ago
Ting and colleagues report the safety and efficacy of combined radiation and immunotherapy in a phase II trial on patients with MSS colorectal or pancreatic cancer and observe that disease control correlates with higher repetitive RNA transcription.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8Immunosuppressive niche engineering at the onset of human colorectal cancer - Nature Communications - 10 month(s) ago
Integration of mathematical modeling, ecological analyses of patient biopsies, and neoantigen heterogeneity suggests recruitment of immunosuppressive cells is key to initializing transformation from adenoma to carcinoma in human colorectal cancer.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 15
Genomic factors, in particular KRAS and TP53 mutation, may assist in patient selection and radiotherapeutic decision-making for patients with oligometastatic CRC. Prospective validation, ideally with genomic correlation of all irradiated metastases, is warranted.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
A8-3 📌Similarly, data suggest that KRAS + TP53 mutation may be associated with poorer local control & Overall Survival after oligometastasis-directed SBRT https://t.co/mThEaDmApb Figure showing local failure #CRCTrialsChat @OncoAlert #CRCSM https://t.co/6phb6WxvRx
-
-
Mashup Score: 6A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation - Full Text View - ClinicalTrials.gov - 1 year(s) ago
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4MAP Kinase Ras Raf Mek Erk signaling - 1 year(s) agoSource: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1What is germline testing? - Colontown University - 1 year(s) ago
Germline testing is done with a routine blood sample. If your oncologist decides that germline testing could be beneficial for you, you will get a
Source: Colontown UniversityCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Clinical Trial Basics 2023 - 1 year(s) ago
We begin the 2023 #CRCTrialsChat with a session on Clinical Trial Basics
Source: WakeletCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 20
Author summary Why was this study done? Recurrence risk remains high in patients who underwent curative-intent surgical resection of colorectal cancer liver metastases (CRLM), with limited additional benefit from pre- or postoperative chemotherapy. There is currently no validated biomarker of recurrence for resected CRLM that could help guide the use of chemotherapy for the individual patient….
Source: journals.plos.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/2G7n792yTL 📌54 pts with resectable CRLM 📌Can post-op ctDNA detect MRD & predict relapse? 📌Value of serial ctDNA during & after chemo? #CRCTrialsChat https://t.co/PjCAv0DCNR
-
https://t.co/2G7n79k9Lj 📌For #CRC pts with resectable liver mets after sx, recurrence risk remains high. Additional benefit from pre-or post-op chemo? 📌No validated biomarker yet 📌ctDNA maybe a promising marker, ctDNA +ve➡️ highly predictive of relapse #CRCTrialsChat https://t.co/RfVZIb2QdC
-
RT @aparna1024: https://t.co/2G7n792yTL 📌54 pts with resectable CRLM 📌Can post-op ctDNA detect MRD & predict relapse? 📌Value of serial ctDN…
-
A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-1) → surgery Primary endpoint= complete response 🔥Early results favorable with 30-50% pCR! https://t.co/hRLnPEzSj9 https://t.co/HiuUXpXetf #CRCTrialsChat